← Back to Search

Other

CC-96673 for Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Celgene

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participant (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF).

Participant must have a history of NHL that has relapsed or progressed.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years after study treatment

Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective for people with a certain type of cancer that has come back or does not respond to other treatments.

Who is the study for?

Adults over 18 with Non-Hodgkin's Lymphoma that has come back or didn't respond to treatment can join. They must be able to follow the study plan, have a performance status showing they're mostly active and well, and meet certain lab value criteria. People with brain-involved cancer symptoms, other active cancers, significant heart issues, recent major surgery, pregnancy, HIV/HBV/HCV infections or on certain immune-suppressing drugs cannot participate.Check my eligibility

What is being tested?

The trial is testing CC-96673 for safety and how well it's tolerated in adults with relapsed/refractory Non-Hodgkin's Lymphoma. It includes two parts: first finding the right dose (Part A) and then seeing how it works at that dose (Part B).See study design

What are the potential side effects?

While specific side effects of CC-96673 are not listed here as this is an early-phase trial aimed at determining safety and tolerability, common side effects from similar treatments may include fatigue, allergic reactions, blood count changes leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years or older and have signed the consent form.

Select...

My non-Hodgkin lymphoma has come back or gotten worse.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years after study treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years after study treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years after study treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose-limiting toxicity (DLT)

Incidence of Adverse Events (AEs)

Maximum tolerated dose (MTD)

Secondary outcome measures

Duration of response (DOR)

Incidence of laboratory-reported positive responses of anti-CC-96673 antibodies

Overall response rate (ORR)

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Administration of CC-96673Experimental Treatment1 Intervention

CC-96673 will be administered on a once weekly (Q1W) or once every 2 weeks (Q2W) schedule

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor

636 Previous Clinical Trials

128,871 Total Patients Enrolled

Eric Kim, MDStudy DirectorCelgene Corporation

1 Previous Clinical Trials

160 Total Patients Enrolled

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,506 Previous Clinical Trials

3,369,430 Total Patients Enrolled

Media Library

CC-96673 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04860466 — Phase 1

Non-Hodgkin's Lymphoma Research Study Groups: Administration of CC-96673

Non-Hodgkin's Lymphoma Clinical Trial 2023: CC-96673 Highlights & Side Effects. Trial Name: NCT04860466 — Phase 1

CC-96673 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04860466 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide an estimate of the number of participants enrolled in this research?

"This clinical trial seeks 100 eligible participants from two main sites: University Of Nebraska Medical Center in Omaha, Nebraska and Local Institution - 202 in Montreal, Quebec."

Answered by AI

Are there any U.S.-based locations where this research is underway?

"The University Of Nebraska Medical Center in Omaha, The Local Institution - 202 of Montreal and the esteemed University of Texas - MD Anderson Cancer Centre in Houston are some of the key sites leading this trail. In addition, there are 9 other medical centres participating."

Answered by AI

What is the ultimate aim of this medical experiment?

"To measure the efficacy of this trial, its primary outcome is evaluated over a year and a half to determine Adverse Events. Other metrics associated with its Secondary Outcomes are Terminal Half-life, Observed Serum Concentration at the End of Dosing Interval, and Total Body Clearance."

Answered by AI

Are there still opportunities to participate in this research experiment?

"According to the clinicaltrials.gov website, this research endeavour initiated on January 20th 2022 is now actively recruiting participants. The trial was last updated November 18th of the same year."

Answered by AI